Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Predictive Oncology is a medical instruments & supplies business based in the US. Predictive Oncology shares (POAI) are listed on the NASDAQ and all prices are listed in US Dollars. Predictive Oncology employs 30 staff and has a trailing 12-month revenue of around $1.6 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $0.61 |
|---|---|
| 52-week range | $0.21 - $1.10 |
| 50-day moving average | $0.40 |
| 200-day moving average | $0.42 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.31 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.607 from 2023-02-06
| 1 week (2023-01-31) | 14.53% |
|---|---|
| 1 month (2023-01-06) | 64.50% |
| 3 months (2022-11-08) | 144.76% |
| 6 months (2022-08-08) | 29.42% |
| 1 year (2022-02-08) | -24.69% |
|---|---|
| 2 years (2021-02-08) | -61.82% |
| 3 years (2020-02-07) | 2.41 |
| 5 years (2018-02-07) | 11.055 |
| Revenue TTM | $1.6 million |
|---|---|
| Gross profit TTM | $933,656 |
| Return on assets TTM | -22.6% |
| Return on equity TTM | -66.11% |
| Profit margin | 0% |
| Book value | $0.38 |
| Market capitalisation | $42.1 million |
TTM: trailing 12 months
We're not expecting Predictive Oncology to pay a dividend over the next 12 months.
Predictive Oncology's shares were split on a 1:10 basis on 28 October 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Predictive Oncology shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Predictive Oncology shares which in turn could have impacted Predictive Oncology's share price.
Over the last 12 months, Predictive Oncology's shares have ranged in value from as little as $0.21 up to $1.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Predictive Oncology's is 1.2033. This would suggest that Predictive Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Predictive Oncology Inc. , a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.